Skip to main content

Advertisement

SpringerLink
Log in

Imaging in Lung Cancer

  • Oncologic Imaging (S Delorme, Section Editor)
  • Published:
Current Radiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To describe the current role of imaging in the detection, staging, therapy planning and response assessment in lung cancer.

Recent Findings

Lung cancer screening using low-dose CT has been shown to reduce mortality in risk groups of active or former smokers and has, thus, been recommended by several societies and organisations worldwide. There remain, however, questions regarding optimum definition of risk factors and screening intervals. Staging criteria for lung cancer have been updated in the 8th edition of the TNM staging to better reflect prognosis. Preliminary research in radiomics in lung cancer has provided data that may add to identification of early lung cancer, prediction of prognosis and therapy response. Targeted systemic therapy has recently had a significant impact in advanced lung cancer both in terms of efficacy and toxicity, but radiologists need to be aware that response assessment criteria differ from those used for classic chemotherapy, and new side effects that may occur.

Summary

Modern imaging, particulary exploiting radiomics will improve early detection, classification, staging, therapy planning and ultimately, hopefully, prognosis in lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

Recently published papers of particular interest have been highlighted as: • Of importance •• Of major importance

  1. Fitzmaurice C, Global Burden of Disease Cancer Collaboration, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3:524–48.

    Article  Google Scholar 

  2. American Cancer Society. Cancer facts and figures 2018. Atlanta: ACS; 2018.

    Google Scholar 

  3. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

    Article  Google Scholar 

  4. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.

    Article  CAS  Google Scholar 

  5. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.

    Article  Google Scholar 

  6. • Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, Paz-Ares L. Lung cancer: current therapies and new targeted treatments. Lancet. 2017; 389: 299–311. https://doi.org/10.1016/s0140-6736(16)30958-8. Comprehensive overview of the current status of early detection of lung cancer and therapeutic concepts including personalized medicine.

    Article  CAS  Google Scholar 

  7. Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, Rice T, Suzuki K, Thomas CF, Travis WD, Wu YL, IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2015;10:990–1003. https://doi.org/10.1097/JTO.0000000000000559.

    Article  PubMed  Google Scholar 

  8. Boiselle PM, Ernst A, Karp DD. Lung cancer detection in the 21st century: potential contributions and challenges of emerging technologies. AJR Am J Roentgenol. 2000;175:1215–21.

    Article  CAS  Google Scholar 

  9. Flehinger BJ, Melamed MR, Zaman MB, Heelan RT, Perchick WB, Martini N. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Memorial Sloan-Kettering study. Am Rev Respir Dis. 1984;130(4):555–60.

    CAS  PubMed  Google Scholar 

  10. Frost JK, Ball WC Jr, Levin ML, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study. Am Rev Respir Dis. 1984;130(4):549–54.

    CAS  PubMed  Google Scholar 

  11. Tockman MS. Survival and mortality from lung cancer in a screened population: the Johns Hopkins Study. Chest. 1986;89(suppl):324S–5S.

    Article  Google Scholar 

  12. Fontana RS, Sanderson DR, Taylor WF, et al. Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Mayo Clinic study. Am Rev Respir Dis. 1984;130(4):561–5.

    CAS  PubMed  Google Scholar 

  13. Kubík A, Polák J. Lung cancer detection: results of a randomized prospective study in Czechoslovakia. Cancer. 1986;57(12):2427–37.

    Article  Google Scholar 

  14. Oken MM, Marcus PM, Hu P, Beck TM, Hocking W, Kvale PA, Cordes J, Riley TL, Winslow SD, Peace S, Levin DL, Prorok PC, Gohagan JK, PLCO Project Team. Baseline chest radiograph for lung cancer detection in the randomized Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Cancer Inst. 2005;97:1832–9.

    Article  Google Scholar 

  15. Grosso M, Priotto R, Ghirardo D, Talenti A, Roberto E, Bertolaccini L, Terzi A, Chauvie S. SOS Study Group Comparison of digital tomosynthesis and computed tomography for lung nodule detection in SOS screening program. Radiol Med. 2017;122:568–74.

    Article  Google Scholar 

  16. • MacMahon H, Naidich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, Mehta AC, Ohno Y, Powell CA, Prokop M, Rubin GD, Schaefer-Prokop CM, Travis WD, Van Schil PE, Bankier AA. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology. 2017; 284: 228–43. https://doi.org/10.1148/radiol.2017161659. Guidelines for the management of incidentally detected pulmonary nodules.

    Article  Google Scholar 

  17. • Lung-RADS Assessment Categories, Version 1.0. American College of Radiology. Lung CT Screening Reporting and Data System (Lung-RADS™) Web site. http://www.acr.org/Quality-Safety/Resources/LungRADS. Guidelines for the management of screening detected nodules.

  18. •• National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365: 395–409. Landmark study demonstrating fort the first time mortality reduction in smokers when screened with low-dose CT.

  19. Kauczor HU, Bonomo L, Gaga M, Nackaerts K, Peled N, Prokop M, Remy-Jardin M, von Stackelberg O, Sculier JP, European Society of Radiology (ESR); European Respiratory Society (ERS). ESR/ERS white paper on lung cancer screening. Eur Radiol. 2015;25:2519–31. https://doi.org/10.1007/s00330-015-3697-0.

    Article  PubMed  PubMed Central  Google Scholar 

  20. De Koning H, Van Der Aalst C, Ten Haaf K, Oudkerk M. 2018 Effects of volume CT lung cancer screening: mortality results of the NELSON randomised controlled population based trial. ABSTRACTS IASLC 19thWorld Conference on Lung Cancer. www.iaslc.org.

  21. Fan L, Fang M, Li Z, Tu W, Wang S, Chen W, Tian J, Dong D, Liu S. Radiomics signature: a biomarker for the preoperative discrimination of lung invasive adenocarcinoma manifesting as a ground-glass nodule. Eur Radiol. 2019;29:889–97.

    Article  Google Scholar 

  22. Hoffman RM, Sanchez R. Lung cancer screening. Med Clin North Am. 2017;101(4):769–85. https://doi.org/10.1016/j.mcna.2017.03.008.

    Article  PubMed  Google Scholar 

  23. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, Escriu C, Peters S, ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:1–21. https://doi.org/10.1093/annonc/mdx222.

    Article  Google Scholar 

  24. TNM Classification of Malignant Tumours—7. Edition. Union for International Cancer Control 2009.

  25. • TNM Classification of Malignant Tumours - 8. Edition. Union for International Cancer Control 2016. Current staging system for lung cancer.

  26. • https://www.iaslc.org/sites/default/files/wysiwyg-assets/iaslc_8th_posters_24x36_2018_final_version_1.pdf. Current staging system for lung cancer.

  27. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7:228–34.

    Article  CAS  Google Scholar 

  28. • Kumar V, Gu Y, Basu S, Berglund A, Eschrich SA, Schabath MB, Forster K, Aerts HJ, Dekker A, Fenstermacher D, Goldgof DB, Hall LO, Lambin P, Balagurunathan Y, Gatenby RA, Gillies RJ (2012) Radiomics: the process and the challenges. Magn Reson Imaging. 2012; 30:1234–48. The article describes the principle and potential applications of radiomics.

    Article  Google Scholar 

  29. Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue RTHM, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE. Walsh S (2019 Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017;14:749–62.

    Article  Google Scholar 

  30. Parekh Vishwa, Jacobs Michael A. Radiomics: a new application from established techniques. Expert Review of Precision Medicine and Drug Development. 2016;1(2):207–26.

    Article  Google Scholar 

  31. • Verma V, Simone CB 2nd, Krishnan S, Lin SH, Yang J, Hahn SM (2017) The rise of radiomics and implications for oncologic management. J Natl Cancer Inst.; 109. Article on the use of radiomics in cancer patients.

  32. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  CAS  Google Scholar 

  33. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweijk J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  Google Scholar 

  34. Choi H. Response evaluation of gastrointestinal stromal tumors. Oncologist. 2008;13(Suppl 2):4–7. https://doi.org/10.1634/theoncologist.13-S2-4.

    Article  PubMed  Google Scholar 

  35. Kalkmann J, Zeile M, Antoch G, Berger F, Diederich S, Dinter D, Fink C, Janka R, Stattaus J, German GIST Imaging Working Group. Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group. Cancer Imaging. 2012;12:126–35. https://doi.org/10.1102/1470-7330.2012.0013.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG. RECIST working group iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143–52.

    Article  Google Scholar 

  37. Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A. Wolchok JD (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 2016;34:1510–7. https://doi.org/10.1200/JCO.2015.64.0391.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors. A Review. JAMA Oncol. 2016;2:1346–53.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic and Interventional Radiology, Marien Hospital Düsseldorf, Academic Teaching Hospital, Rochusstr. 2, 40479, Düsseldorf, Germany

    Stefan Diederich

  2. Department of Haematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Academic Teaching Hospital, Rochusstr. 2, 40479, Düsseldorf, Germany

    Aristoteles A. N. Giagounidis

Authors
  1. Stefan Diederich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aristoteles A. N. Giagounidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Diederich.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Oncologic Imaging.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Diederich, S., Giagounidis, A.A.N. Imaging in Lung Cancer. Curr Radiol Rep 7, 19 (2019). https://doi.org/10.1007/s40134-019-0330-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s40134-019-0330-z

Keywords

Search

Navigation